Rid Annette, Wendler David
Institute of Biomedical Ethics, University of Zurich.
Kennedy Inst Ethics J. 2011 Jun;21(2):141-79. doi: 10.1353/ken.2011.0007.
Essentially all guidelines and regulations require that biomedical research studies have an acceptable risk-benefit profile. However, these documents offer little concrete guidance for implementing this requirement and determining when it is satisfied. As a result, those charged with risk-benefit evaluations currently assess the risk-benefit profile of biomedical research studies in unsystematic ways, raising concern that some research participants are not being protected from excessive risks and that some valuable studies involving acceptable risk are being rejected. The present paper aims to address this situation by delineating the first comprehensive framework, which is based on existing guidelines and regulations as well as the relevant literature, for risk-benefit evaluations in biomedical research.
基本上所有的指导方针和法规都要求生物医学研究具有可接受的风险效益比。然而,这些文件对于如何落实这一要求以及如何判定何时达到要求几乎没有提供具体的指导。因此,目前负责风险效益评估的人员在评估生物医学研究的风险效益比时缺乏系统性,这引发了人们的担忧,即一些研究参与者没有得到充分保护,免受过度风险的侵害,而一些涉及可接受风险的有价值的研究却被拒绝。本文旨在通过勾勒首个全面框架来解决这一问题,该框架基于现有指导方针、法规以及相关文献,用于生物医学研究中的风险效益评估。